Effect of Ferrous Ascorbate versus Liposomal iron on hemoglobinConcentration and Iron indices in 6 to 59 months age Children With Nutritional Iron-Deficiency Anemia:A Double blinded single centre Randomized clinical trial - Nil

开始日期2023-09-01

申办/合作机构-

NCT05489952 / Recruiting临床4期IIT

Efficacy and Safety of Perioperative Iron Supplementation for Postoperative Rehabilitation of Geriatric Hip Fractures: a Multicenter, Randomized, Controlled Trial.

Geriatric hip fracture is an important disease that affects the health life of the elderly in China. Geriatric hip fracture is often complicated by a variety of comorbidities due to advanced age. And anemia is a common comorbidity. At present perioperative management of geriatric hip fracture, transfusion is only indicated for moderate and severe anemia, while no special medical intervention for mild anemia in China. More and more studies have found that iron can not only correct anemia, but also improve cardiac function, patients' quality of life and function. This study investigated the effect of perioperative iron supplementation on activity tolerance in elderly patients with hip fracture complicated with iron deficiency anemia. The study was a randomized, parallel controlled clinical study. Due to the requirements of the ethics committee, the unblinded setting was cancelled due to ethical considerations. Research will be grouped according to whether to accept iron supplementation treatment, are divided into 2 groups, respectively, iron treatment group and the traditional method. The method of randomization was stratified block randomization. The experimental group added to the intravenous iron sucrose during perioperative period according to the degree of iron deficiency. If there is still a iron deficiency or anemia at discharge, oral ferrous lactate is added after discharge. The outcomes include 6-minute walk distance, Harris score, EQ-5D score six months after surgery, perioperative blood transfusion rate, and so on in the two groups.

开始日期2022-09-15

申办/合作机构-

100 项与硫酸亚铁/维生素C 相关的临床结果

登录后查看更多信息

100 项与硫酸亚铁/维生素C 相关的转化医学

登录后查看更多信息

100 项与硫酸亚铁/维生素C 相关的专利（医药）

登录后查看更多信息

11,025

项与硫酸亚铁/维生素C 相关的文献（医药）

2024-08-01·Current pediatric reviews

Iron Deficiency Anemia: An Updated Review

Review

作者: Lam, Joseph M ; Wong, Alex H C ; Leung, Alexander K C ; Li, Xiuling ; Hon, Kam Lun

Background::

Worldwide, iron deficiency anemia is the most prevalent nutritional deficiency disorder and the leading cause of anemia in children, especially in developing countries. When present in early childhood, especially if severe and prolonged, iron deficiency anemia can result in neurodevelop- mental and cognitive deficits, which may not always be fully reversible even following the correction of iron deficiency anemia.

Objective::

This article aimed to familiarize physicians with the clinical manifestations, diagnosis, evaluation, prevention, and management of children with iron deficiency anemia.

Methods::

A PubMed search was conducted in February 2023 in Clinical Queries using the key term "iron deficiency anemia". The search strategy included all clinical trials (including open trials, non-randomized controlled trials, and randomized controlled trials), observational studies (including case reports and case series), and reviews (including narrative reviews, clinical guidelines, and meta-analyses) published within the past 10 years. Google, UpToDate, and Wikipedia were also searched to enrich the review. Only pa- pers published in the English literature were included in this review. The information retrieved from the search was used in the compilation of the present article.

Results::

Iron deficiency anemia is most common among children aged nine months to three years and during adolescence. Iron deficiency anemia can result from increased demand for iron, inadequate iron intake, decreased iron absorption (malabsorption), increased blood loss, and rarely, defective plasma iron transport. Most children with mild iron deficiency anemia are asymptomatic. Pallor is the most frequent presenting feature. In mild to moderate iron deficiency anemia, poor appetite, fatigability, lassitude, leth- argy, exercise intolerance, irritability, and dizziness may be seen. In severe iron deficiency anemia, tachy- cardia, shortness of breath, diaphoresis, and poor capillary refilling may occur. When present in early childhood, especially if severe and prolonged, iron deficiency anemia can result in neurodevelopmental and cognitive deficits, which may not always be fully reversible even with the correction of iron deficien- cy anemia. A low hemoglobin and a peripheral blood film showing hypochromia, microcytosis, and marked anisocytosis, should arouse suspicion of iron deficiency anemia. A low serum ferritin level may confirm the diagnosis. Oral iron therapy is the first-line treatment for iron deficiency anemia. This can be achieved by oral administration of one of the ferrous preparations, which is the most cost-effective medi- cation for the treatment of iron deficiency anemia. The optimal response can be achieved with a dosage of 3 to 6 mg/kg of elemental iron per day. Parenteral iron therapy or red blood cell transfusion is usually not necessary.

Conclusion::

In spite of a decline in prevalence, iron deficiency anemia remains a common cause of ane- mia in young children and adolescents, especially in developing countries; hence, its prevention is im- portant. Primary prevention can be achieved by supplementary iron or iron fortification of staple foods. The importance of dietary counseling and nutritional education cannot be overemphasized. Secondary prevention involves screening for, diagnosing, and treating iron deficiency anemia. The American Acad- emy of Pediatrics recommends universal laboratory screening for iron deficiency anemia at approximately one year of age for healthy children. Assessment of risk factors associated with iron deficiency anemia should be performed at this time. Selective laboratory screening should be performed at any age when risk factors for iron deficiency anemia have been identified.

2024-04-26·Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Anaemia in CKD—treatment standard

Review

作者: Macdougall, Iain C

ABSTRACT:

Anaemia is one of the most common complications of chronic kidney disease (CKD), having a significant impact on quality of life, and is also associated with a number of adverse clinical outcomes. Its pathogenesis is multifactorial, caused largely by an inadequate production of erythropoietin from the diseased kidneys, with iron deficiency, inflammation, shortened red cell lifespan and enhanced blood loss also being contributory factors. The management of this condition was transformed in the late 1980s by the advent of recombinant human erythropoietin (epoetin), and treatment paradigms have developed over the last three decades, largely focusing on a combination of epoetin or its analogues (erythropoiesis-stimulating agents; ESAs) along with iron supplementation, often administered intravenously due to increased hepcidin levels limiting iron absorption from the gut. Indeed, in patients with early CKD and iron deficiency, iron per se may be sufficient to improve the anaemia, delaying the need for ESA therapy. Other causes of anaemia should be excluded and corrected (if possible) before resorting to treatment with ESAs and iron. More recently, the hypoxia-inducible factor–prolyl hydroxylase inhibitors have entered the therapeutic arena; these are orally active agents that upregulate endogenous erythropoietin production as well as a number of iron-regulatory genes which may also enhance erythropoiesis. The latter drugs are highly efficacious, and may have advantages in inflammatory conditions causing resistance to conventional ESA therapy, but concerns exist regarding their safety, particularly in the longer term. This article reviews the current standards of treatment, as well as recent novel developments in the management of anaemia in CKD.

2024-04-01·Critical care medicine

Pharmacotherapy for Reducing RBC Transfusion for Patients in the ICU: A Systematic Review and Network Meta-Analysis

Review

作者: Kataoka, Yuki ; Taito, Shunsuke ; Yoshihiro, Shodai ; Hongo, Takashi ; Yamamoto, Mariko

OBJECTIVES::

To determine optional therapeutic strategies by comparing monotherapies and combination therapies to reduce RBC transfusion requirement for patients in the ICU.

DATA SOURCES::

MEDLINE, CENTRAL, and Embase were searched for studies published from database inception until July 2023.

DATA EXTRACTION::

We included randomized controlled trials comparing erythropoiesis-stimulating agents (Epo), iron, combination therapy with iron and Epo, hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vitamin D3 (VD3), and placebo/no treatment. A frequentist network meta-analysis (NMA) was performed using a random effects model, and the confidence in NMA was rated.

DATA SYNTHESIS::

Of 117 eligible studies, 75 studies (15,091 patients) were included in the quantitative analysis. Compared with placebo/no treatment, the combination therapy reduces the requirement for RBC transfusion (risk ratio [RR]: 0.60; 95% CI, 0.49–0.74; confidence rating: moderate). The Epo or iron monotherapy may reduce the requirement for RBC transfusion (RR: 0.81; 95% CI, 0.63–1.04; confidence rating: low; RR: 0.83; 95% CI, 0.70–0.98; confidence rating: low, respectively). Combination therapy may not increase the prevalence of both venous thromboembolism (VTE) (RR: 0.73; 95% CI, 0.25–2.08; confidence rating: low) and infection. Epo monotherapy may not increase the prevalence of VTE but may increase that of infections (RR: 1.27; 95% CI, 0.94–1.73; confidence rating: low). Iron monotherapy may not increase the prevalence of both VTE and infection. Evidence for VD3 and HIF-PHI remains uncertain.

CONCLUSIONS::

Combination therapy with iron and Epo likely reduces the requirement for RBC transfusion and may be less harmful than other therapies.

项与硫酸亚铁/维生素C 相关的新闻（医药）

2023-12-01

·Science Daily

Meteorites likely source of nitrogen for early Earth

Micrometeorites originating from icy celestial bodies in the outer Solar System may be responsible for transporting nitrogen to the near-Earth region in the early days of our solar system. Micrometeorites originating from icy celestial bodies in the outer Solar System may be responsible for transporting nitrogen to the near-Earth region in the early days of our solar system. That discovery was published today in Nature Astronomy by an international team of researchers, including University of Hawai'i at Manoa scientists, led by Kyoto University. Nitrogen compounds, such as ammonium salts, are abundant in material born in regions far from the sun, but evidence of their transport to Earth's orbital region had been poorly understood. "Our recent findings suggests the possibility that a greater amount of nitrogen compounds than previously recognized was transported near Earth, potentially serving as building blocks for life on our planet," says Hope Ishii, study co-author and affiliate faculty at the Hawai'i Institute of Geophysics and Planetology in the UH Manoa School of Ocean and Earth Science and Technology (SOEST). Like all asteroids, Ryugu is a small, rocky object that orbits the sun. The Japan Aerospace Exploration Agency's Hayabusa2 spacecraft explored Ryugu and brought material from its surface back to Earth in 2020. This intriguing asteroid is rich in carbon and has undergone significant space weathering caused by micrometeorite collisions and exposure to charged ions streaming from the sun. In this study, the scientists aimed to discover clues about the materials arriving near Earth's orbit, where Ryugu is currently located, by examining the evidence of space weathering in Ryugu samples. Using an electron microscope, they found that the surface of the Ryugu samples are covered with tiny minerals composed of iron and nitrogen (iron nitride: Fe4N). "We proposed that tiny meteorites, called micrometeorites, containing ammonia compounds were delivered from icy celestial bodies and collided with Ryugu," said Toru Matsumoto, lead author of the study and assistant professor at Kyoto University. "The micrometeorite collisions trigger chemical reactions on magnetite and lead to the formation of the iron nitride." The iron nitride was observed on the surface of magnetite, which consists of iron and oxygen atoms. When magnetite is exposed to the space environment, oxygen atoms are lost from the surface by the irradiation of hydrogen ions from the sun (solar wind) and by heating through micrometeorite impact. These processes form metallic iron on the very surface of the magnetite, which readily reacts with ammonia, creating ideal conditions for synthesis of iron nitride.

2023-11-16

·GlobeNewswire-Health Care

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

MELBOURNE, Australia and SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to ATH434 was presented at the Society for Neuroscience that took place November 11-15, 2023, in Washington, D.C. The poster entitled, “Potent Antioxidant and Mitochondrial-protectant Effects of ATH434, a Novel Inhibitor of α-Synuclein Aggregation with Moderate Iron-binding Affinity,” presents new data indicating that ATH434 can preserve mitochondrial function after oxidative injury and exert direct anti-oxidant activity independent of its iron binding properties. These features were not observed with another iron binding agent approved for treating iron overload that was also investigated. The study was run under the direction of Dr. Daniel J. Kosman, Distinguished Professor of Biochemistry at the State University of New York at Buffalo. David Stamler, M.D., Chief Executive Officer of Alterity, commented, “These exciting new data underscore the potential of ATH434 as a treatment for neurodegenerative diseases, including Parkinson’s disease and related disorders. We have long known that ATH434 is able to reduce labile iron which, when elevated, can drive oxidative stress. The demonstrated mitochondrial protection may reveal additional mechanisms that augment its ability to slow disease progression. We are grateful for the valued contributions from our collaborators in Dr. Kosman’s laboratory at SUNY-Buffalo.” The study, authored by Dr. Danielle Bailey, investigated the efficacy of ATH434 and comparator agents as mitochondrial protectants using a menadione-induced model of oxidative stress in a neuronal cell line. A suite of in-solution assays detailed the mechanisms underlying ATH434’s direct antioxidant capacity. The poster presentation can be accessed on Alterity’s website under The Science page. About ATH434 Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 studies demonstrating the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal models of MSA. ATH434 is currently being studied in two clinical trials: Study ATH434-201 is a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with early-stage MSA and Study ATH434-202 is an open-label Phase 2 Biomarker trial in patients with more advanced MSA. ATH434 has been granted Orphan drug designation for the treatment of MSA by the U.S. FDA and the European Commission. About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com. Authorisation & Additional informationThis announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited. Investor and Media Contacts: AustraliaHannah Howlettwe-aualteritytherapeutics@we-worldwide.com+61 450 648 064 U.S.Remy Bernardaremy.bernarda@iradvisory.com +1 (415) 203-6386 Forward Looking Statements This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

临床结果临床2期临床1期孤儿药

2023-10-25

·PRNewswire

Renibus Announces First Patient Enrolled in PROTECT Phase 3 Study of RBT-1 to Reduce Post-operative Complications After Cardiothoracic Surgery

Pivotal trial will evaluate the effect of RBT-1 as a preconditioning agent in people undergoing cardiothoracic surgeryEstimated 600K CABG and valve repair surgeries in US/year, creating a large initial market for RBT-1PROTECT enrollment on track, NDA filing anticipated early 2026 SOUTHLAKE, Texas, Oct. 25, 2023 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced that the first patient has been dosed in the pivotal Phase 3 PROTECT trial of RBT-1, the Company's first-in-a-new-class preconditioning agent under investigation to reduce post-operative complications following cardiothoracic surgery. PROTECT is expected to be conducted at approximately 35 sites in the United States and Canada. Continue Reading Post-operative complications from cardiothoracic surgery represent a major unmet medical need. In the United States (US), there are approximately 600,000 CABG, valve repair, and related procedures conducted annually, with 66% of patients having complications that result in $6.5 billion in unnecessary healthcare costs. This represents a significant and growing initial market for RBT-1, which if approved, would be the first and only approved pharmacological therapy to reduce the risk of post operative complications following cardiothoracic surgery. RBT-1 (stannic protoporfin/iron sucrose), a fixed dose combination product given once intravenously over 1-2 hours, 24-48 hours before surgery, is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways. In a completed Phase 2 study, RBT-1 demonstrated statistically significant positive data in primary and several secondary endpoints, with reduced time in the ICU, shortened patient recovery time and fewer hospital readmissions. "We are pleased to initiate our PROTECT Phase 3 study of RBT-1. This milestone represents a significant step towards addressing the unmet needs associated with post-operative complications after cardiothoracic surgery, and underscores our commitment to transforming this treatment landscape," said Frank Stonebanks, Co-CEO of Renibus. "With our pivotal trial now underway in our PROTECT program, we are considering ways to expand the opportunity with RBT-1 across a wide spectrum of procedures and post-operative complications, including potentially transplant surgeries, TAVR's (trans aortic valve replacements) and thoracic aortic aneurysms. We believe that RBT-1 has broad "pipeline-in-a-product" potential, and we look forward to executing well in Phase 3 and bringing our product to patients in need." PROTECT is a Phase 3, Rand omized, Double-Blind, Placebo-Controlled S tudy to Evaluate the Effect of RBT-1 on Reducing the Risk of Post-Operative Complica tions in Subjects Undergoing Cardiac Surgery. The study is a randomized, double-blind, multi-center, placebo-controlled trial evaluating the effect of RBT-1 in approximately 400 patients. The primary endpoint is a severity-based composite hierarchy using the Win-Ratio or Finkelstein-Schoenfeld Method that includes the following: death, AKI requiring dialysis, ICU days, and 30-day cardiopulmonary readmission rates. Secondary and exploratory objectives include time on the ventilator, need for blood products, new onset atrial fibrillation, delirium, hospital length of stay, cost effective analyses and safety. Top line results are expected mid-2025. Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery, New York-Presbyterian Hospital, Weill Cornell Medicine, added, "The cardiac surgery community is grateful for Renibus' commitment to bringing a new treatment option forward for patients undergoing cardiac surgery. RBT-1 is a potentially transformational pre-conditioning product, and I am enthusiastic about the initial results demonstrated in our patients." About RBT-1 RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surgery. Renibus completed the Phase 2 study of RBT-1 (NCT04564833) in February 2023 and announced positive final results from this study in May 2023. In October 2023, Renibus initiated enrollment and administration of RBT-1 in its PROTECT Phase 3 pivotal study. RBT-1 was granted Breakthrough Therapy designation status from the U.S. FDA to reduce the risk of complications in patients undergoing cardiothoracic surgery. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardiorenal and metabolic diseases. Renibus' first-in-class lead program is RBT-1, currently being evaluated in a pivotal Phase 3 PROTECT study. RBT-3 is a novel, low molecular weight iron nanoparticle that has the potential to rapidly resolve iron deficiency and may reduce the risk of cisplatin-induced nephrotoxicity. RBT-9 (stannic protoporfin) is a potent anti-inflammatory and antioxidant drug with broad spectrum anti-viral properties. It has been investigated in a 42-patient Phase 2, randomized, placebo-controlled trial in high-risk patients with COVID-19. The data from this trial indicated the RBT-9 has the potential to significantly improve clinical outcomes in life threatening viral infections. Additional pre-clinical work is underway to help inform the clinical development strategy. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Frank Stonebanks Co-CEO, Renibus [email protected] SOURCE Renibus Therapeutics

临床2期临床3期突破性疗法

100 项与硫酸亚铁/维生素C 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB13257

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
缺铁性贫血	中国	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EHA2022	N/A	新型冠状病毒感染	60	Sucrosomial® iron	鑰齋衊獵範憲積築鏇範(鹹艱膚簾窪憲憲衊積廠) = 願鬱選遞獵繭膚壓鹽壓壓願壓觸廠遞鏇繭鑰網 (鏇觸範願製齋構顧襯襯 ) 更多	-	2022-06-10
				iron oral formulation (No iron support)	鑰齋衊獵範憲積築鏇範(鹹艱膚簾窪憲憲衊積廠) = 積夢襯廠餘願選齋網構壓願壓觸廠遞鏇繭鑰網 (鏇觸範願製齋構顧襯襯 ) 更多
ASN2021	N/A	FGF23	20	EPO with parenteral Fe supplement	獵夢願膚窪繭簾窪製襯(廠鏇遞鏇鹹繭襯鏇顧蓋) = 糧鬱壓糧願鏇壓憲廠鹽廠鑰齋蓋襯壓憲範醖簾 (餘顧鑰襯獵憲獵鏇艱鏇 )	积极	2021-10-27
				EPO without parenteral Fe supplement	獵夢願膚窪繭簾窪製襯(廠鏇遞鏇鹹繭襯鏇顧蓋) = 網憲選鑰廠鬱餘膚膚醖廠鑰齋蓋襯壓憲範醖簾 (餘顧鑰襯獵憲獵鏇艱鏇 )
ASN2020	N/A	慢性肾病	170	Iron isomaltoside (HDLF1)	鬱膚艱糧鬱膚鹽衊願積(簾醖鏇繭積鹽淵鹽獵壓) = 構窪膚餘餘膚襯範網範願繭膚鬱齋艱膚觸鹹鹹 (築網鏇鬱廠蓋築製襯鹽 ) 更多	积极	2020-10-19
ERA2020	N/A	HF \| diabetes	2,141	High-dose intravenous iron	網壓衊窪艱網廠淵膚衊(網獵醖齋襯壓廠顧窪遞) = 憲廠膚窪鏇構蓋構遞夢製範積壓遞廠醖構壓鏇 (鏇糧範襯淵積構觸觸壓 )	积极	2020-06-06
				Low-dose intravenous iron	網壓衊窪艱網廠淵膚衊(網獵醖齋襯壓廠顧窪遞) = 齋範艱膚遞淵簾鏇夢壓製範積壓遞廠醖構壓鏇 (鏇糧範襯淵積構觸觸壓 )
EHA2019	N/A	-	36	Iron Sulphate	醖觸膚選網製範積鹹選(構選廠齋憲構襯醖範範) = 繭壓獵顧範壓鬱廠構鹽遞醖鬱餘衊顧齋鹹簾蓋 (遞繭獵積衊築鏇鑰獵顧 )	-	2019-05-16
				Sucrosomial® Iron	醖觸膚選網製範積鹹選(構選廠齋憲構襯醖範範) = 繭構壓夢鏇蓋繭壓醖鹹遞醖鬱餘衊顧齋鹹簾蓋 (遞繭獵積衊築鏇鑰獵顧 )
EHA2019	N/A	骨髓增生异常综合征	45	Group A (sodium ferrigluconate)	艱鏇壓願簾鬱遞蓋遞獵(廠簾選繭繭顧齋網簾窪) = 壓襯憲鏇鹽壓窪壓範鏇獵窪獵網憲餘願簾簾齋 (壓繭襯鹽積壓範餘觸蓋 ) 更多	-	2019-05-16
				Group B (sucrosomial iron)	艱鏇壓願簾鬱遞蓋遞獵(廠簾選繭繭顧齋網簾窪) = 淵鬱鹽齋壓簾製範鑰觸獵窪獵網憲餘願簾簾齋 (壓繭襯鹽積壓範餘觸蓋 ) 更多
ASN2018	N/A	低磷血症 FGF23	-	IV ferric carboxymaltose	醖築鑰鹹鏇蓋夢憲糧鹹(選積鬱糧鹹選蓋築簾簾) = numbness, tingling and muscle cramps 鹹顧鹹積選衊齋觸簾鏇 (淵鹽範衊齋壓蓋鹽鏇鏇 )	不佳	2018-10-23
				Oral phosphorus supplementation
ASN2018	N/A	霍奇金淋巴瘤 MDA-LDL \| NTBI \| TSAT ... 更多	-	Oral ferrous sulfate 105mg	鹹廠構蓋蓋廠網餘鹽膚(範蓋顧遞鏇築衊構遞願) = 壓醖憲憲窪鏇築糧糧壓築膚鬱襯製膚壓蓋遞鹽 (淵範醖構簾簾襯顧夢蓋, 104 ~ 320) 更多	积极	2018-10-23
				Oral Iron Administration (OIA)	觸窪製窪窪夢壓鏇繭衊(蓋構遞構鹹餘鹹襯艱襯) = 衊廠遞衊廠鬱簾築簾膚餘遞獵蓋繭淵糧製醖範 (顧餘夢鹹選積鹹鑰衊繭, 68 ~ 124)
NCT00992823 (Pubmed \| BMC Public Health)	N/A	贫血	99	iron supplementation (Weekly Group)	鏇網襯淵網夢選醖簾艱(淵鏇窪製窪窪襯鑰構壓) = 艱衊醖積夢鏇壓製積鑰製範鬱顧獵襯齋鏇淵淵 (製憲範艱鹹願顧鹹窪獵 ) 更多	-	2013-01-10
				iron supplementation (Cyclical Group)	鏇網襯淵網夢選醖簾艱(淵鏇窪製窪窪襯鑰構壓) = 繭網艱鬱艱築艱夢積繭製範鬱顧獵襯齋鏇淵淵 (製憲範艱鹹願顧鹹窪獵 ) 更多
NCT01092377 (Pubmed \| Int J Psychophysiol)	N/A	铁缺乏	321	Iron supplementation	餘夢糧鹽觸遞鏇築壓糧(願壓範願積構簾蓋鹹鬱): OR = 2.31 (95% CI, 1.13 ~ 4.73)	-	2013-01-01
				iron supplementation (Placebo)